Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma

Part of paid clinical trials in New Haven, Connecticut.

Sponsor: Yale University
Study ID: NCT02784483
Phase: PHASE1
Status: Terminated

Conditions

Asymptomatic Myeloma

Eligibility Criteria

Sex: ALL
Age: 18 Years - 90 Years
Healthy Volunteers: Not accepted

Interventions

Atezolizumab (1200mg via IV infusion) — DRUG
Patients will get atezolizumab every 21 days for up to 1 year

Study Details

The purpose of this pilot study is to gain initial insights into the biologic and clinical effects of Atezolizumab in patients with Asymptomatic Multiple Myeloma (AMM). The data may provide novel insights into anti-PDL-1-induced immunologic changes, which could potentially be relevant to its future development in Multiple Myeloma (MM) and other indications.

Key Dates

Start date: Feb 10, 2017
Status verified: Feb 2020
Primary completion: Sep 15, 2017
Completion: Apr 22, 2019

Study Design

Enrollment: 2 participants (actual)
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Arms

Experimental: Atezolizumab (1200mg via IV infusion)

Primary Outcome Measure

Prevalence of anti-SOX2 reactive T cells after Anti-PDL1 therapy [ Time Frame: Up to 1 year ]

Locations (1)

Facility	City	State	ZIP	Site coordinators
Yale University	New Haven	Connecticut	06520	-

Find similar trials in New Haven, CT

By research site

Yale University· New Haven, CT